The lack of sufficient attention to lipid-based formulations prior to clinical testing on insoluble molecules, especially those with low or variable oral bioavailability in conventional formu-lations, has led to a dearth of applications for this technology and only 2–4% of the commercially available drug products formulated relies on such technology